Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. More Details
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Ocular Therapeutix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OCUL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: OCUL's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: OCUL exceeded the US Pharmaceuticals industry which returned 14.6% over the past year.
Return vs Market: OCUL exceeded the US Market which returned 38.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Ocular Therapeutix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StMost Shareholders Will Probably Find That The CEO Compensation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Is Reasonable
4 weeks ago | Simply Wall StHave Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insiders Been Selling Their Stock?
1 month ago | Simply Wall StNeed To Know: The Consensus Just Cut Its Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates For 2021
Is Ocular Therapeutix undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OCUL ($13.51) is trading below our estimate of fair value ($47.96)
Significantly Below Fair Value: OCUL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OCUL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: OCUL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCUL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCUL is overvalued based on its PB Ratio (12.3x) compared to the US Pharmaceuticals industry average (3.2x).
How is Ocular Therapeutix forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCUL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OCUL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OCUL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OCUL's revenue (39.2% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: OCUL's revenue (39.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCUL's Return on Equity is forecast to be high in 3 years time
How has Ocular Therapeutix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCUL is currently unprofitable.
Growing Profit Margin: OCUL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCUL is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: OCUL has a negative Return on Equity (-157.06%), as it is currently unprofitable.
How is Ocular Therapeutix's financial position?
Financial Position Analysis
Short Term Liabilities: OCUL's short term assets ($228.1M) exceed its short term liabilities ($27.4M).
Long Term Liabilities: OCUL's short term assets ($228.1M) exceed its long term liabilities ($132.2M).
Debt to Equity History and Analysis
Debt Level: OCUL's debt to equity ratio (57.6%) is considered high.
Reducing Debt: OCUL's debt to equity ratio has increased from 19.2% to 57.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCUL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ocular Therapeutix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OCUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCUL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Antony Mattessich (53 yo)
Mr. Antony Mattessich has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since July 26, 2017. Mr. Mattessich served as Managing Director of Mundipharma International Limited fro...
CEO Compensation Analysis
Compensation vs Market: Antony's total compensation ($USD2.16M) is about average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.
Experienced Management: OCUL's management team is considered experienced (3.4 years average tenure).
Experienced Board: OCUL's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCUL insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.5%.
Ocular Therapeutix, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ocular Therapeutix, Inc.
- Ticker: OCUL
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.031b
- Shares outstanding: 76.29m
- Website: https://www.ocutx.com
Number of Employees
- Ocular Therapeutix, Inc.
- 24 Crosby Drive
- United States
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel pl...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/21 06:23|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.